Publication:
How do we make progress in phenotyping patients with LUT such as OAB and underactive detrusor, including using urine markers and microbiome data, in order to personalize therapy? ICI-RS 2023 - Part 1

dc.contributor.coauthorAgro, Enrico Finazzi
dc.contributor.coauthorRosato, Eleonora
dc.contributor.coauthorWagg, Adrian
dc.contributor.coauthorSinha, Sanjay
dc.contributor.coauthorSpicchiale, Claudia Fede
dc.contributor.coauthorSerati, Maurizio
dc.contributor.coauthorMancini, Vito
dc.contributor.coauthorde Rijk, Mathijs
dc.contributor.coauthorWein, Alan
dc.contributor.coauthorAbrams, Paul
dc.contributor.coauthorKheir, George Bou
dc.contributor.kuauthorTarcan, Tufan
dc.contributor.researchcenter 
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.unit 
dc.date.accessioned2024-12-29T09:39:10Z
dc.date.issued2024
dc.description.abstractIntroductionOveractive bladder (OAB) and Underactive bladder (UAB) could be associated with metabolic syndrome, affective disorders, sex hormone deficiency, changes in urinary microbiota, functional gastrointestinal disorders, or autonomic nervous system dysfunction.ObjectivesThe aim of this Think Tank was to provide a guide on how to investigate OAB and/or detrusor underactivity (DU) patients to better clarify the underlying pathophysiology and possibly personalize the treatment.MethodsA compendium of discussion based on the current evidence related to phenotyping patients with OAB or DU investigating metabolic, neurogical, psychological and gastrointestinal aspects with the aim to personalize the treatment.Results and ConclusionsThe article emphasizes the critical significance of adopting a comprehensive yet tailored approach to phenotyping patients with lower urinary tract symptoms, such as OAB and UAB. The intricate interplay between the lower urinary tract and various factors, metabolic, neurological, psychological, and gastrointestinal can define unique LUT profiles, enabling personalized therapies to replace the one-size-fits-all approach.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue6
dc.description.openaccess 
dc.description.publisherscopeInternational
dc.description.sponsors 
dc.description.volume43
dc.identifier.doi10.1002/nau.25377
dc.identifier.eissn1520-6777
dc.identifier.issn0733-2467
dc.identifier.link 
dc.identifier.quartileQ3
dc.identifier.scopus2-s2.0-85181513211
dc.identifier.urihttps://doi.org/10.1002/nau.25377
dc.identifier.urihttps://hdl.handle.net/20.500.14288/22922
dc.identifier.wos1136685400001
dc.keywordsAffective disorders
dc.keywordsAutonomic nervous system dysfunction
dc.keywordsGastrointestinal disorders
dc.keywordsMetabolic syndrome
dc.keywordsMicrobiome
dc.keywordsOveractive bladder
dc.keywordsUnderactive bladder
dc.languageen
dc.publisherWiley
dc.relation.grantno 
dc.rights 
dc.sourceNeurourology and Urodynamics
dc.subjectUrology and nephrology
dc.titleHow do we make progress in phenotyping patients with LUT such as OAB and underactive detrusor, including using urine markers and microbiome data, in order to personalize therapy? ICI-RS 2023 - Part 1
dc.typeJournal article
dc.type.other 
dspace.entity.typePublication
local.contributor.kuauthorTarcan, Tufan

Files